{
  "id": "602e84e61cb411341a000126",
  "type": "yesno",
  "question": "Is Tocilizumab (Actemra) used to block/antagonize the  IL-6 receptor?",
  "ideal_answer": "yes, tocilizumab (actemra) is used to block/antagonize the  il-6 receptor.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/22870473",
    "http://www.ncbi.nlm.nih.gov/pubmed/20953198",
    "http://www.ncbi.nlm.nih.gov/pubmed/18071945",
    "http://www.ncbi.nlm.nih.gov/pubmed/33262810",
    "http://www.ncbi.nlm.nih.gov/pubmed/32365119",
    "http://www.ncbi.nlm.nih.gov/pubmed/31164961",
    "http://www.ncbi.nlm.nih.gov/pubmed/20065633",
    "http://www.ncbi.nlm.nih.gov/pubmed/29952844",
    "http://www.ncbi.nlm.nih.gov/pubmed/24155139",
    "http://www.ncbi.nlm.nih.gov/pubmed/16102523",
    "http://www.ncbi.nlm.nih.gov/pubmed/23844337",
    "http://www.ncbi.nlm.nih.gov/pubmed/30021477",
    "http://www.ncbi.nlm.nih.gov/pubmed/19368420",
    "http://www.ncbi.nlm.nih.gov/pubmed/20402381",
    "http://www.ncbi.nlm.nih.gov/pubmed/31796986",
    "http://www.ncbi.nlm.nih.gov/pubmed/20305672",
    "http://www.ncbi.nlm.nih.gov/pubmed/33269653",
    "http://www.ncbi.nlm.nih.gov/pubmed/31809899",
    "http://www.ncbi.nlm.nih.gov/pubmed/28841363",
    "http://www.ncbi.nlm.nih.gov/pubmed/22334272",
    "http://www.ncbi.nlm.nih.gov/pubmed/33264466"
  ],
  "snippets": [
    {
      "text": "Preliminary clinical results have indicated that antagonism of the IL-6 receptor (IL-6R), including with the FDA-approved humanized monoclonal antibody tocilizumab, can improve the outcomes of patients with severe or critical COVID-19 while maintaining a good safety profile.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33262810",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tocilizumab, an anti-IL-6 receptor antibody, and corticosteroids were initially used to treat the increase in acute inflammatory proteins and the anasarca, resulting in decreased cytokine levels. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33269653",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tocilizumab, a monoclonal antibody against the IL-6 receptor, was initiated at a dose of 8 mg/kg every 4 weeks.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29952844",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "we randomly assigned patients with type 2 diabetes or obesity to intravenous tocilizumab (an IL-6 receptor antagonist) ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31796986",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " Clinical studies are investigating whether tocilizumab (anti-IL-6 receptor) can help preserve beta cell function in patients recently diagnosed with T1D",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31809899",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tocilizumab (RoActemra or Actemra) is a recombinant humanized monoclonal antibody that acts as an interleukin (IL)-6 receptor antagonist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/19368420",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To increase the number of cycles of antigen binding and lysosomal degradation, we engineered tocilizumab (Actemra), an antibody against the IL-6 receptor (IL-6R), to rapidly dissociate from IL-6R within the acidic environment of the endosome (pH 6.0) while maintaining its binding affinity to IL-6R in plasma (pH 7.4).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20953198",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tocilizumab (Actemra; Genentech, Inc) is the first biologic therapy targeting the cytokine interleukin 6 (IL-6).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22334272",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "over, our findings showed that combination of tocilizumab (Actemra; Roche), an anti-IL-6R monoclonal antibody, with carboplatin synergistically inhibited growth and proliferation of the EOC cells and the most direct axis for IL-6 gene expression was NF-\u03baB pathway.CONC",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30021477",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Roche is co-developing tocilizumab (Actemra, RoActemra), a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, with Chugai Pharmaceutical.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20065633",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tocilizumab (TCZ) is a compound that inhibits the IL-6 receptor.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20402381",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tocilizumab (TCZ), is a recombinant humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody which has a main use in the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis (sJIA) and polyarticular juvenile idiopathic arthritis (pJIA).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28841363",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "the US Food and Drug Administration accepted a complete-response submission for the use of Actemra (tocilizumab), the first humanized IL-6 receptor-inhibiting monoclonal antibody, for the treatment of RA. Although thi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20305672",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "increase the number of cycles of antigen binding and lysosomal degradation, we engineered tocilizumab (Actemra), an antibody against the IL-6 receptor (IL-6R), to rapidly dissociate from IL-6R within the acidic environment of the endosome (pH 6.0) while maintaining its binding affinity to IL-6R in plasma (pH 7.4). Studies usin",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20953198",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " present study, we have shown that the humanized anti-IL-6 receptor tocilizumab (Actemra) is also a potent inhibitor of IL-8 in TNBC cells. Similar ef",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33264466",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Roche is co-developing tocilizumab (Actemra, RoActemra), a humanized anti-interleukin-6 receptor (IL-6R) monoclonal antibody, with Chugai Pharmaceutical. Tocili",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20065633",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "tory gene activation is inhibited in vitro by tocilizumab, a humanized antibody to IL6 receptor (IL6R). Tocilizumab",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/23844337",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "These lines of evidence indicate that tocilizumab is able to bind to both sIL-6R and mIL-6R and to inhibit IL-6 binding to its receptors, leading to the blockade of the IL-6 signaling through both sIL-6R and mIL-6R, but not block the signaling of other IL-6 family cytokines.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16102523",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tocilizumab inhibits signal transduction mediated by both mIL-6R and sIL-6R, but not by the receptors of other members of IL-6 cytokine family.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16102523",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In addition, tocilizumab had the ability to bind to human IL-6R expressing COS-7 cells and to suppress the growth of the IL-6-dependent myeloma cell line, KPMM2.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16102523",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "To characterize the biological activity of tocilizumab, a humanized anti-human interleukin-6 receptor (IL-6R) monoclonal antibody, we examined its binding activity to both soluble IL-6R (sIL-6R) and membrane bound IL-6R (mIL-6R) and its neutralizing activity to other IL-6 family cytokines.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16102523",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tocilizumab inhibited the proliferation of BaF/IL-6R induced by IL-6, but did not inhibit the proliferation of BaF/IL-11R, BaF/OSMR, BaF/LIFR and BaF/CNTFR cells induced by their corresponding cytokines.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16102523",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Moreover, tocilizumab suppressed the IL-6/sIL-6R complex-induced proliferation of human gp130-transfected cell, BAF-h130.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16102523",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In addition, tocilizumab had the ability to dissociate IL-6 and sIL-6R from their preformed complex.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16102523",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ELISA assay demonstrated that tocilizumab bound to sIL-6R and inhibited IL-6 binding to sIL-6R in a dose-dependent manner.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/16102523",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tocilizumab recognizes both the membrane-bound and the soluble form IL-6R and specifically blocks IL-6 actions.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18071945",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Humanized antihuman IL-6 receptor antibody, tocilizumab.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18071945",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Tocilizumab is a humanized antihuman IL-6 receptor antibody designed using genetic engineering technology.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18071945",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tocilizumab is expected to ameliorate the autoimmune inflammatory diseases with IL-6 overproduction and has been clinically developed as a therapeutic agent for RA, systemic-onset and articular types of JIA, Crohn's disease, etc.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/18071945",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tocilizumab/Actemra is an anti-IL-6R antibody, which can competitively block IL-6 binding to the IL-6R.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31164961",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tocilizumab (TCZ; RoActemra\u00ae or Actemra\u00ae) is a recombinant humanized monoclonal antibody that acts as an interleukin 6 (IL-6) receptor antagonist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/22870473",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In 2009 the US Food and Drug Administration accepted a complete-response submission for the use of Actemra (tocilizumab), the first humanized IL-6 receptor-inhibiting monoclonal antibody, for the treatment of RA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/20305672",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tocilizumab binds to the interleukin-6 receptor (IL-6R) and thereby blocks signaling of the pro-inflammatory cytokine IL-6.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32365119",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Tocilizumab (RoActemra(\u00ae); Actemra(\u00ae)) is a recombinant humanized monoclonal antibody that acts as an interleukin-6 receptor antagonist.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/24155139",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "Yes"
}